Lennon David James 4

What Happened

• Lennon David James, Chief Executive Officer of Whitehawk Therapeutics (WHWK), sold a total of 260,427 shares in three broker-assisted transactions tied to tax withholding obligations. The sales were: 102,395 shares at $3.51 ($359,406) on 2026-04-06; 94,087 shares at $3.43 ($322,718) on 2026-04-07; and 63,945 shares at $3.40 ($217,413) on 2026-04-08. Total proceeds across the three disposals were approximately $899,537. These disposals are sales (S) and were executed to satisfy tax withholding related to vested restricted stock units (see footnote F1).

Key Details

• Transaction dates and prices:
  • 2026-04-06: Sold 102,395 shares @ $3.51 — $359,406
  • 2026-04-07: Sold 94,087 shares @ $3.43 — $322,718
  • 2026-04-08: Sold 63,945 shares @ $3.40 — $217,413
• Total shares sold: 260,427; total proceeds: ~$899,537.
• Footnote: F1 — broker-assisted sale to satisfy the reporting person’s tax withholding obligations in connection with the vesting of restricted stock units.
• Filing: Form 4 was filed on 2026-04-08 (period of report begins 2026-04-06); this filing appears to be within the standard reporting window (not marked late).
• Shares owned after transaction: Not specified in the information provided in this summary (refer to the full Form 4 for exact post-transaction holdings).

Context

• These were broker-assisted sales for tax withholding on vested RSUs (a common, non-directional reason executives sell shares). Such transactions generally reflect tax-related liquidity needs rather than a straightforward negative signal about the company.
• For retail investors: purchases by insiders can be a stronger signal of confidence than routine sales. Always check the full Form 4 for holdings, grant/vesting details, and any 10b5-1 plan disclosures before drawing conclusions.